ZIOPHARM Oncology (ZIOP) Releases Earnings Results, Misses Expectations By $-0.01 EPS

ZIOPHARM Oncology (ZIOP) reported quarterly earnings results on Tuesday, May-10-2016. The company reported $-0.09 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.08. The company posted revenue of $1.97 million in the period, compared to analysts expectations of $1.89 million. The company’s revenue was up 623.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.69 EPS.

ZIOPHARM Oncology opened for trading at $6.79 and hit $7.095 on the upside on Friday, eventually ending the session at $7, with a gain of 2.19% or 0.15 points. The heightened volatility saw the trading volume jump to 18,28,152 shares. Company has a market cap of $922 M.

In a different news, on Nov 23, 2015, Caesar J Belbel (COO, CLO, and Secretary) sold 153,333 shares at $12.84 per share price. According to the SEC, on Jun 11, 2015, Francois Lebel (Executive Vice President R&D) sold 50,000 shares at $10.12 per share price. On Jun 5, 2015, Kevin G Lafond (Vice Pres., Treasurer, & CAO) sold 57,500 shares at $9.67 per share price, according to the Form-4 filing with the securities and exchange commission.

ZIOPHARM Oncology Inc. is a biopharmaceutical company. The Company is engaged in the acquisition development and commercialization of a portfolio of cancer therapies through synthetic biology. The Company’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Company’s clinical stage product candidate Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12 or IL-12 a potent naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex for the treatment of metastatic melanoma and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).


Leave a Reply

ZIOPHARM Oncology - Is it time to Sell?

Top Brokerage Firms are advising their investors on ZIOPHARM Oncology. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.